Q1 EARNINGS: Boston loses rhythm, Alere, Sorin
This article was originally published in Clinica
Executive Summary
Boston Scientific’s share price fell 6% after it reported disappointing results for its cardiac rhythm management (CRM) division, with a particularly weak performance from US its implantable cardioverter-defibrillators (ICDs).